SEC Form 4 · accession 0001493152-18-008649

PRESSURE BIOSCIENCES INC · PBIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 11, 2018

Accepted (ET)

Jun 13, 2018 · 9:55 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000830656

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
SERIES AA CONVERTIBLE PREFERRED STOCK	$2.50	Jun 11, 2018	J	20	A	Jun 11, 2018	Jun 11, 2019	COMMON STOCK	20,200	20	D
COMMON STOCK WARRANT^F1	$3.50	Jun 11, 2018	J	20,200	A	Jun 11, 2018	Jun 11, 2023	COMMON STOCK	20,200	20,200	D
COMMON STOCK WARRANT^F1	$3.50	Jun 11, 2018	J	2,739	A	Mar 31, 2016	Mar 31, 2021	COMMON STOCK	2,739	2,739	D

F1On June 11, 2018, Pressure BioSciences, Inc. (the "Issuer") entered into a letter agreement with Mr. Urdea (the "Reporting Person"). The Reporting Person previously held a convertible debenture with a face value of $50,600 (the "Debenture") and warrants to purchase common stock (the "Debenture Warrants"). Pursuant to the letter agreement, the Reporting Person agreed to convert the principal due to him pursuant to the Debenture into shares of Series AA Convertible Preferred Stock with a conversion price of $2.50 per share. The Reporting Person was also: (a) issued amended Debenture Warrants (originally issued on March 31, 2016) such that the exercise price is now $3.50 per share; and (b) issued a new warrant with an exercise price of $3.50 per share to purchase such number of shares of common stock as equal 100% of the number of shares of common stock issuable upon conversion of the Series AA Convertible Preferred Stock shares received as a result of the Debenture conversion.